…T cells. HLA is part of the major histocompatibility complex (MHC), which includes fragments of proteins called peptides. When these peptides are from a cancerous protein, HLA presents them to…
…(BCH), ChainLink (LINK), Compound (COMP), Curve (CRV), Dai (DAI), Decentraland (MANA), Dogecoin (DOGE), Enjin Coin (ENJ), Fantom (FTM), Filecoin (FIL), Gemini Dollar (GUSD), Injective Protocol (INJ), Kyber Network (KNC), Litecoin…
…2003. “Since the day it was founded, ACGT has been committed to achieving a better understanding of cancer biology and immunology, translating that understanding into game-changing clinical therapies,” says Dr….
…on gene therapy protocols at the University of Pittsburgh. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery, and author of more than 500 scientific…
…Cancer Gene Therapy funding, continues to be life-changing and life-saving for many people. As the focus shifts to solid tumors, Dr. June is again leading the medical community forward to…
…weeks continue to work for patients with ‘liquid’ cancers such as leukemia, there is still a significant need to reduce the time and cost of producing these complex therapies. Building…
…available to patients after just one other kind of treatment (usually chemotherapy) has failed. Impressive response from patients to Kymriah in study The latest approval comes after a crucial phase…
…up for email communications to get the latest news from ACGT in the field of cell and gene therapy. Page sources Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells,…
…which is a combination of blood vessels and tissue that separates the central nervous system from the rest of the body. In particular, this barrier is one of the main…
…cells’ specific characteristics – such as protein antigens serving as fingerprint identification – are crucial. These cells react quickly and with force when they come into contact with other cancer…
…around commercial CAR T-cell dosing and didn’t know if higher doses would affect toxicity and compromise outcomes, or support enhanced anti-leukemia effect. This data has direct clinical applicability, as it…
Researchers at the University of Pennsylvania’s Perelman School of Medicine studied the use of CAR T-cell therapy following surgery for breast cancer. Scientists have developed and tested CAR T-cell therapies…
…Ms. Lavery is responsible for programmatic initiatives, including leadership of the Academic Research Program and the Biotechnology Investment Program. “This is my dream job,” says Ms. Lavery. “It combines science…
Kevin Honeycutt was named CEO and president of Alliance for Cancer Gene Therapy in December 2018 and elected to its board of directors in June 2022. As chief executive officer,…
…been hailed as one of the most promising breakthroughs in cancer therapy, and its full potential beyond the treatment of B-cell malignancies remains to be realized. Successful completion of the…
…diseases as well. Ovarian cancer is one of the most common and frequently life-threatening malignancies affecting women in the U.S. today: about 25,000 new cases will be diagnosed with the…
…GM-CSF tumor vaccines in a mouse model (year 1). 2. Conduct a clinical trial in MDS testing K562/GM-CSF vaccination integrated with the systemic agent(s) identified in aim 1 as…
